• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200-1210.
  • 3
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
  • 4
    Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009; 101: 908-915.
  • 5
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000; 4: 567-579.
  • 6
    Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26: 3503-3510.
  • 7
    Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008; 15: 165-174.
  • 8
    Mayo SC, Austin DF, Sheppard BC, et al. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer. 2010; 116: 2932-2940.
  • 9
    Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008; 37: 352-357.
  • 10
    Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996; 223: 273-279.
  • 11
    Naseef O, Adham M, Hervieu V, Le Borgne J, Partensky C. Long-term survival (superior to 20 years) after pancreaticoduodenectomy for pancreatic duct adenocarcinoma: report of 2 cases. Hepatogastroenterology. 2008; 55: 1110-1111.
  • 12
    Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008; 247: 456-462.
  • 13
    American Joint Commission on Cancer, American Cancer Society. Cancer Staging Manual 7th ed. New York, NY: Springer; 2010.
  • 14
    Merrill RM, Henson DE, Ries LA. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum. 1998; 41: 1097-1106.
  • 15
    Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009; 27: 5938-5943.
  • 16
    Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010; 210: 755-766.
  • 17
    Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer. 1995; 76: 237-242.
  • 18
    Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognosis for long-term survivors of cancer. Ann Oncol. 2007; 18: 1408-1413.
  • 19
    Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007; 141: 610-618.
  • 20
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 21
    Cox D. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
  • 22
    Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. 2nd ed. New York, NY: John Wiley & Sons; 1999.
  • 23
    May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 1998; 4: 109-120.
  • 24
    Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991; 161: 120-124; discussion 124-125.
  • 25
    Bleyer A, Choi M, Fuller CD, Thomas CR Jr, Wang SJ. Relative lack of conditional survival improvement in young adults with cancer. Semin Oncol. 2009; 36: 460-467.
  • 26
    Choi M, Fuller CD, Thomas CR Jr, Wang SJ. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol. 2008; 109: 203-209.
  • 27
    Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: Surveillance, Epidemiology, and End Results data. Cancer. 2001; 92: 2211-2219.
  • 28
    Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004; 240: 293-298.